ART for Prevention: Critical Issues WEAC1
Please enter your email :
Type:
Oral Abstract Session Back
Venue: Session Room 3
Time: 11:00 - 12:30, 22.07.2009
Code: WEAC1
Chairs: Javier Lama, Peru
Connie Celum, United States
Session recording provided by International AIDS Society



Presentations in this session:

11:00
WEAC101
Abstract
Powerpoint		Is the reduction of HIV transmission risk while prescribed antiretroviral therapy (ARVT) different for men and women? Results from discordant couples in Rwanda and Zambia
Presented by Patrick Sullivan, United States
P. Sullivan1, K. Kayitenkore2, E. Chomba3, E. Karita2, L. Mwananyanda3, C. Vwalika3, M. Conkling3, N. Luisi4, A. Tichacek4, S. Allen4
1Emory University Rollins School of Public Health, Department of Epidemiology, Atlanta, United States, 2Projet San Francisco, Kigali, Rwanda, 3Zambia Emory HIV Research Project, Lusaka, Zambia, 4Emory University, Rwanda-Zambia HIV Research Group, Atlanta, United States

11:15
WEAC102
Abstract
Powerpoint		Tolerability of post-exposure prophylaxis (PEP) of HIV infection with the combination of tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation (Truvada® + Kaletra®)
Presented by Christian Rabaud, France
W. Tosini1,2, P. Muller3, T. Prazuck4, G. Benabdelmoumen2, E. Peyrouse5, B. Christian6, Y. Quertainmont7, E. Bouvet1,2, C. Rabaud1,8
1Groupe d'Etude sur le Risque d'exposition des Soignants aux Agents Infectieux (GERES), PARIS, France, 2Hopital Bichat-Claude Bernard, Paris, France, 3Hôpital Beauregard, Thionville, France, 4Centre Hospitalier Régional, Orléans, France, 5Hôpital Sainte Marguerite, Marseille, France, 6Centre Hospitalier Régional, Metz, France, 7Hôpital Bicêtre, Paris, France, 8COREVIH Lorraine Champagne Ardenne ; Centre Hospitalier et Universitaire, Nancy, France

11:30
WEAC103
Abstract
Powerpoint		Bone mineral density (BMD) in a population of healthy HIV-negative young African adults enrolling in a pre-exposure prophylaxis (PrEP) trial in Botswana
Presented by Lynn Paxton, United States
E. Buliva1, C. Vite San Pedro1, R. Mutanhaurwa1, P. Kebaabetswe1, E. Jooste2, S. Johnson1, T. Sukalac1, L. Paxton3, M.C. Thigpen1,3
1BOTUSA, HIV Prevention Research Division, Gaborone, Botswana, 2Medical Imaging Botswana, Gaborone, Botswana, 3Centers for Disease Control and Prevention (CDC), Division of HIV/AIDS Prevention, Epidemiology Branch, Atlanta, United States

11:45
WEAC104
Abstract
Powerpoint		Tenofovir DF/emtricitabine/raltegravir (TDF/FTC/RAL) appears safe and well-tolerated for non-occupational post-exposure prophylaxis (NPEP)
Presented by Kenneth Mayer, United States
K. Mayer1,2, M. Mimiaga1,3, M. Gelman1, J. Trufant1, S. Maynard1, P. McMorrow1
1Fenway Health, The Fenway Institute, Boston, United States, 2Brown University, Infectious Disease Division, Providence, Virgin Islands, U.S., 3Harvard Medical School, Psychiatry, Boston, United States

12:00
WEAC105
Abstract
Powerpoint		The combined impact of male circumcision, condom use and HAART coverage on the HIV-1 epidemic in South Africa: a mathematical model
Presented by Viviane Dias Lima, Canada
V. Lima1, A. Anema1, R. Wood2, D. Moore1, R. Harrigan1, E. Mills1, R. Hogg1, J. Montaner1
1British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada, 2Desmond Tutu HIV Foundation, Cape Town, South Africa

Powerpoints presentations
Is the reduction of HIV transmission risk while prescribed antiretroviral therapy (ARVT) different for men and women? Results from discordant couples in Rwanda and Zambia - Sullivan

Tolerability of post-exposure prophylaxis (PEP) of HIV infection with the combination of tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation (Truvada® + Kaletra®) - Rabaud

Bone mineral density (BMD) in a population of healthy HIV-negative young African adults enrolling in a pre-exposure prophylaxis (PrEP) trial in Botswana - Paxton

Tenofovir DF/emtricitabine/raltegravir (TDF/FTC/RAL) appears safe and well-tolerated for non-occupational post-exposure prophylaxis (NPEP) - Mayer

The combined impact of male circumcision, condom use and HAART coverage on the HIV-1 epidemic in South Africa: a mathematical model - Lima



Rapporteur report

Track C report by Drs Guy De Bruyn


The session on “ART for Prevention: Critical Issues” included presentations covering both antiretroviral treatment of HIV infection and innovations in pre- and post-exposure prophylaxis.

Patrick Sullivan presented an analysis of data from a serodiscordant couples cohort in Zambia and Rwanda examining whether the reduction in transmission risk they have previously noted in relation to ART use is differential by gender. Sullivan described the careful case examination they had performed, in order to as accurately as possible define ART exposure. In their cohort, ART use was associated with reduced incidence of HIV transmission (IRR 0.21). As the transmissions from treated patients all were among couples with a female partner receiving ART, they could not definitively conclude that there were any differences between transmission rates by gender.

Charles Rabaud presented findings from a study of the tolerability of a Tenofovir-Emtricitabine plus Lopinavir-Ritonavir for post-exposure prophylaxis. Based on comparisons to prior historical regimens, tolerability of the new regimen was improved, fewer individuals discontinued PEP due to adverse events, and the regimen offers a reduced pill burden.

Lynn Paxton described a substudy that examined bone mineral density of healthy HIV-uninfected persons enrolled in a trial of TDF-FTC for pre-exposure prophylaxis. The substudy enrolled 102 men and 114 women, finding low BMD at 3 anatomic sites in 4.2% of subjects. A surprisingly high rate of osteopenia was noted among male participants. Osteopenia was related to nutritional status, as defined by body mass index.

Use of raltegravir-containing triple therapy regimens for non-occupational PEP were presented by Ken Mayer. He noted that raltegravir-containing regimens were better tolerated than AZT-3TC-protease options, and completion rates were higher. No seroconversions occurred among the 51 persons treated thus far on this trial.

The session concluded with a presentation by Viviane Lima on a modeling exercise undertaken to examine the relative impacts on the South African epidemic of scaled up ART, male circumcision, and supporting improvements in condom use. Their preliminary results suggest that improving ART coverage and condom use could best limit the HIV epidemic.

 

 


   

   

    The organizers reserve the right to amend the programme.
Contact Us | Site map © 2009 International AIDS Society